Physician
Psychiatry
Dr. Christopher J. Kratochvil, MD
|
|
Give Review
Doctor Christopher J. Kratochvil, MD works in the field of Psychiatry. He attended Creighton University School of Medicine. Creighton University School of Medicine is ranked 79 in research and 78 in primary care medicine He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Christopher J. Kratochvil is a published doctor and has 100 publications published. The lastest was: 'Personal protective equipment processes and rationale for the Nebraska Biocontainment Unit during the 2014 activations for Ebola virus disease.'
Publications
- Personal protective equipment processes and rationale for the Nebraska Biocontainment Unit during the 2014 activations for Ebola virus disease.
- Nebraska Biocontainment Unit patient discharge and environmental decontamination after Ebola care.
- Safety considerations in the laboratory testing of specimens suspected or known to contain ebola virus.
- Efficacy and Safety Extrapolation Analyses for Atomoxetine in Young Children with Attention-Deficit/Hyperactivity Disorder.
- A randomized trial of edivoxetine in pediatric patients with attention-deficit/hyperactivity disorder.
- Pharmacotherapy of pediatric attention-deficit/hyperactivity disorder.
- An Open-Label Safety and Pharmacokinetics Study of Duloxetine in Pediatric Patients with Major Depression.
- Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double...
- Developments in pediatric psychopharmacology: focus on stimulants, antidepressants, and antipsychotics.
- A double-blind, placebo-controlled study of atomoxetine in young children with ADHD.
- The evidence-based pharmacological treatment of paediatric ADHD.
- Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials.
- From TADS and SOFTADS to TORDIA and beyond: what's new in the treatment of adolescent depression?
- Service use and costs of care for depressed adolescents: who uses and who pays?
- An exploratory analysis of the impact of family functioning on treatment for depression in adolescents.
- Dysfunctional attitudes scale perfectionism: a predictor and partial mediator of acute treatment outcome among clinically depressed adolescents.
- The dysfunctional attitudes scale: psychometric properties in depressed adolescents.
- Treatment response in depressed adolescents with and without co-morbid attention-deficit/hyperactivity disorder in the Treatment for Adolescents with Depression Study.
- Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial.
- Suicidal events in the Treatment for Adolescents With Depression Study (TADS).
- Review of ADHD pharmacotherapies: advantages, disadvantages, and clinical pearls.
- Review of pediatric attention deficit/hyperactivity disorder for the general psychiatrist.
- Remission and recovery in the Treatment for Adolescents with Depression Study (TADS): acute and long-term outcomes.
- iPLEDGE allegiance to the pill: evaluation of year 1 of a birth defect prevention and monitoring system.
- Ethnic Differences in Attributions and Treatment Expectancies for Adolescent Depression.
- Cost-effectiveness of treatments for adolescent depression: results from TADS.
- Achievement and maintenance of sustained response during the Treatment for Adolescents With Depression Study continuation and maintenance therapy.
- Attention deficit hyperactivity disorder in preschool children.
- Emotional expression in children treated with ADHD medication: development of a new measure.
- Antidepressant prescribing practices for the treatment of children and adolescents.
- Diagnosing and managing complicated ADHD.
- Ethics and the prescription pad.
- Research knowledge among the participants in the Treatment for Adolescents With Depression Study (TADS).
- Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment.
- Pharmacological management of bipolar disorder in a youth with diabetes.
- AACAP 2005 Research Forum: speeding the adoption of evidence-based practice in pediatric psychiatry.
- Pharmacotherapy for anxiety disorders in children and adolescents: an evidence-based medicine review.
- Antidepressant management in the context of suicidal ideation.
- High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.
- Factors associated with recruitment and screening in the Treatment for Adolescents With Depression Study (TADS).
- Pharmacotherapy of aggression in a 9-year-old with ADHD.
- A manual-based intervention to address clinical crises and retain patients in the Treatment of Adolescents With Depression Study (TADS).
- A pilot study of atomoxetine in young children with attention-deficit/hyperactivity disorder.
- Is there a role for clozapine in the treatment of children and adolescents?
- Pharmacological management of a youth with ADHD and a seizure disorder.
- Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?
- Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning.
- Pharmacological management of a youth with ADHD, marijuana use, and mood symptoms.
- Effects of long-term atomoxetine treatment for young children with attention-deficit/hyperactivity disorder.
- Pharmacological management of a teen with significant alcohol use and depression.
- Pharmacotherapy of ADHD in young children.
- Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder.
- Less is more: inpatient management of a child with complex pharmacotherapy.
- Selecting an antidepressant for the treatment of pediatric depression.
- Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable?
- Pharmacological management of preschool ADHD.
- Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
- Comparative efficacy of cognitive behavioral therapy, fluoxetine, and their combination in depressed adolescents: initial lessons from the treatment for adolescents wi...
- Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, ...
- Pharmacological management of new-onset bipolar disorder.
- Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms.
- Pharmacological management of agitation and aggression in an adolescent with autism.
- Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder.
- Pharmacological management of treatment-induced insomnia in ADHD.
- Pharmacological management of treatment-resistant pediatric depression.
- The assessment of attention-deficit/hyperactivity disorder in rural primary care: the portability of the American Academy of Pediatrics guidelines to the "real wo...
- Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
- The link between health-related quality of life and clinical symptoms among children with attention-deficit hyperactivity disorder.
- Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes.
- Developing strategies for psychopharmacological studies in preschool children.
- Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
- Pharmacotherapy of childhood anxiety disorders.
- Atomoxetine and methylphenidate treatment in children with ADHD: a prospective, randomized, open-label trial.
- Stereoisomers in Psychiatry: The Case of Escitalopram.
- Safety profile of atomoxetine in the treatment of children and adolescents with ADHD.
- Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
- Update on atomoxetine in the treatment of attention-deficit/hyperactivity disorder.
- Assessment of safety and long-term outcomes of initial treatment with placebo in TADS.
- Off-label psychopharmacologic prescribing for children: history supports close clinical monitoring.
- Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy.
- Assessing the efficacy of treatments for ADHD : overview of methodological issues.
- Beyond the ''typical'' patient: treating attention-deficit/hyperactivity disorder in preschoolers and adults.
- Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
- Emotional expression during attention-deficit/hyperactivity disorders treatment: initial assessment of treatment effects.
- Low-dose atomoxetine for maintenance treatment of attention-deficit/hyperactivity disorder.
- Innovations and recent trends in the treatment of ADHD.
- The role of stimulants in the treatment of preschool children with attention-deficit hyperactivity disorder.
- Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003.
- Possible involvement of alpha-2A adrenergic receptors in attention deficit hyperactivity disorder: radioligand binding and polymorphism studies.
- Atomoxetine in the treatment of attention deficit hyperactivity disorder.
- Atomoxetine: a selective noradrenaline reuptake inhibitor for the treatment of attention-deficit/hyperactivity disorder.
- An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder.
- Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder.
- Do children and adolescents with ADHD respond differently to atomoxetine?
- Linkage analysis of attention deficit hyperactivity disorder.
- AACAP 2002 research forum: placebo and alternatives to placebo in randomized controlled trials in pediatric psychopharmacology.
- Remission and residual symptoms after short-term treatment in the Treatment of Adolescents with Depression Study (TADS).
- Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study.
- A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD.
Doctors Specialties
- Psychiatry
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Duke University Hospital -
Creighton University -
Creighton University School of Medicine
Helpful Reviews
Similar Doctors
|
|
James F. Sorrell II, CRNA
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Sriram Ramaswamy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jay A. Rich, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marilou K. Woodard, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce D. Gutnik, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Yetunde A. Ogunleye, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James R. Dunlap, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew D. Dobbertin, MD |
|
|
Dr. Bryan J. Beals, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joshua Lotfallah, MD |
|
|
Dr. Arun Sharma, MD |